Key Highlights

  • Loss per share was USD 1.05 against an estimate of a USD 1.36 loss.
  • Net loss was USD 29.02 million, against USD 20.95 million a year earlier.
  • Cash and short-term investments totaled USD 359.7 million at September 30.
  • Dosing of 25 participants in the registrational Embolden trial is complete.

Neurogene (NASDAQ:NGNE) reported a third quarter 2026 loss per share of USD 1.05, against an estimate of a USD 1.36 loss and a USD 0.99 loss in the third quarter of 2025. Net loss was USD 29.02 million, compared with USD 20.95 million in the prior-year quarter.

The loss from operations was USD 32.38 million, against USD 23.80 million a year earlier. The company reported the figures in its quarterly filing for the period ended September 30, 2026, and gave an update on its NGN-401 gene therapy program for Rett syndrome.

Operating Expenses and Interest Income

Research and development expenses were USD 23.52 million, compared with USD 17.24 million. General and administrative expenses were USD 8.85 million, compared with USD 6.56 million. Total operating expenses were USD 32.38 million, against USD 23.80 million.

Interest income was USD 3.24 million, compared with USD 2.74 million, an increase of USD 0.5 million. For the nine months ended September 30, 2026, total operating expenses were USD 102.40 million, against USD 75.80 million, and interest income was USD 7.55 million, against USD 8.87 million.

Net loss for the nine months was USD 94.45 million, compared with USD 65.62 million in the same period of 2025. The nine-month loss per share was USD 3.90, against USD 3.11. Research and Development expenses for the period were USD 74.14 million, against USD 54.37 million, and general and administrative expenses were USD 28.26 million, against USD 21.43 million.

NGN-401 Clinical Program

The company completed dosing of 25 participants in its ongoing registrational trial of NGN-401, called Embolden, a single-arm, open-label, baseline-controlled trial evaluating the 1E15 vg dose of NGN-401 gene therapy in females with Rett syndrome. The filing states that topline results are anticipated in the second half of 2027.

In June 2026, the company announced positive long-term clinical data from its Phase 1/2 trial with a data cutoff date of June 16, 2026. The filing states that all treatment-related adverse events in the Phase 1/2 trial have been mild (Grade 1) or moderate (Grade 2) in severity, and that the majority are known potential risks of AAV and have resolved or are resolving.

Liquidity and Runway

Cash and cash equivalents were USD 78.94 million at September 30, 2026, compared with USD 103.85 million at the prior Balance Sheet date, and short-term investments were USD 280.78 million, compared with USD 165.17 million. The company reported cash, cash equivalents and short-term investments totaling USD 359.7 million and an accumulated Deficit of USD 447.1 million.

Following the completion of its July 2026 public offering, the company believes its existing cash, cash equivalents and investments are sufficient to fund operations into the first quarter of 2029.

Neurogene Q3 2026 Earnings: Key Takeaways

Neurogene reported a third quarter 2026 loss per share of USD 1.05 and a net loss of USD 29.02 million. Research and development expenses were USD 23.52 million, and cash, cash equivalents and short-term investments totaled USD 359.7 million.